Login / Signup

Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer.

Mau-Ern PohSivasubramaniam BalakrishnanSin Nee TanMuhammad Adil Zainal AbidinChong Kin LiamJiunn Liang TanYong Kek PangArvindran AlagaLye Mun ThoSoon Hin How
Published in: Translational lung cancer research (2024)
-mutated advanced NSCLC patients who failed first-line treatment with first- or second-generation EGFR TKIs due to T790M mutation.
Keyphrases
  • epidermal growth factor receptor
  • advanced non small cell lung cancer
  • tyrosine kinase
  • low dose
  • high dose
  • small cell lung cancer
  • wild type
  • smoking cessation